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DOI 10.1016/j.ccr.2010.09.009SUMMARYThe molecular events underlying the progression of T-lymphoblastic lymphoma (T-LBL) to acute T-lympho-
blastic leukemia (T-ALL) remain elusive. In our zebrafish model, concomitant overexpression of bcl-2 with
Myc accelerated T-LBL onset while inhibiting progression to T-ALL. The T-LBL cells failed to invade the
vasculature and showed evidence of increased homotypic cell-cell adhesion and autophagy. Further analysis
using clinical biopsy specimens revealed autophagy and increased levels of BCL2, S1P1, and ICAM1 in
human T-LBL compared with T-ALL. Inhibition of S1P1 signaling in T-LBL cells led to decreased homotypic
adhesion in vitro and increased tumor cell intravasation in vivo. Thus, blockade of intravasation and hema-
tologic dissemination in T-LBL is due to elevated S1P1 signaling, increased expression of ICAM1, and
augmented homotypic cell-cell adhesion.INTRODUCTION
T-lymphoblastic lymphoma (T-LBL) and acute T-lymphoblastic
leukemia (T-ALL) are distinct clinical presentations of related
malignant diseases that arise in developing thymocytes. The
clinical distinction between T-ALL and T-LBL is based on the
extent of tumor cell dissemination within the bone marrow and
peripheral blood. T-LBL patients typically present with a large
anterior mediastinal mass and little evidence of dissemination.
However, stage IV T-LBL disease is characterized by distant
dissemination through the blood and up to 25% bone marrow
cellularity consisting of T-lymphoblasts. Cases are classified asSignificance
Thymic lymphomas are closely related to thymic leukemias, bu
astinal mass in some patients while disseminating rapidly as T
increased BCL2 levels possess a distinct cellular phenotype,
autophagy. This T-LBL phenotype results from elevated levels
sion and block intravasation. Our results show that AKT activa
intravasation, suggesting that PI3K-AKT inhibitors may be he
invade and disseminate.
CT-ALL if the T-lymphoblasts comprise more than 25% of the
bone marrow cells at presentation, regardless of the extent of
thymic or nodal involvement. About one-third of T-ALL cases
present with a mediastinal mass, while the remaining two-thirds
lack radiographic evidence of a mediastinal mass and generally
have high numbers of circulating T lymphoblasts (Sen and
Borella, 1975; Goldberg et al., 2003). Although T-LBL and
T-ALL share many morphologic, immunophenotypic, and geno-
typic features (Cairo et al., 2005), a recent comparison of T-ALL
versus T-LBL gene expression profiles (Raetz et al., 2006)
suggests intrinsic differences in growth regulatory pathways
that may distinguish between these two malignancies and couldt it is unknownwhy T-LBL remains highly localized as amedi-
-ALL in others. Here, we demonstrate that T-LBL cells with
including impaired vascular invasion, metabolic stress, and
of S1P1 and ICAM1 that promote homotypic cell-cell adhe-
tion is one mechanism that can overcome the T-LBL block in
lpful in preventing T-LBL cells from acquiring the ability to
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Figure 1. Bcl-2 Promotes Onset but Inhibits the Progression of Myc-Induced T-LBL in Zebrafish
(A) Rate of tumor onset in three transgenic zebrafish lines: hsp70-Cre;rag2-EGFP-bcl-2 (Cre;bcl-2) double-transgenic fish (n = 31; green line), rag2-LDL-EGFP-
Myc;hsp70-Cre (Myc;Cre) double-transgenic fish (n = 26; blue line), and rag2-LDL-EGFP-Myc;hsp70-Cre;rag2-EGFP-bcl-2 (Myc;Cre;bcl-2) triple-transgenic fish
(n = 32; red line).
(B) Rate of T-LBL progression to T-ALL in Myc;Cre (n = 13; blue line) versus Myc;Cre;bcl-2 (n = 21; red line) transgenic fish.
(C–H) Localized GFP-labeled tumors first arose as T-LBL in Myc;Cre (C; 112-day) and Myc;Cre;bcl-2 (F; 119-day) transgenic fish; widespread dissemination
leading to leukemia was seen within 11 weeks after T-LBL onset in Myc;Cre fish (D and ,E), but not in Myc;Cre;bcl-2 triple transgenics (G and H).
(I–L) GFP-positive T-LBL tumor cells (n = 5 per group) transplanted into the peritoneum of irradiated wild-type hosts. Tumor cells from theMyc;Cre double-trans-
genic fish disseminated rapidly (I–J), while those from theMyc;Cre;bcl-2 triple-transgenics remained localized (K and L). Scale bar for (C)–(H) and (I)–(L), 1 mm.
See also Figure S1.
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therapies.
MYC is a potent proto-oncogene that is aberrantly expressed
in a broad spectrum of human cancers including leukemia and
lymphoma (Nesbit et al., 1999; Pelengaris et al., 2002). In
T-ALL and T-LBL, aberrant expression ofMYC generally occurs
downstream of activated NOTCH signaling. Activatingmutations
in theNOTCH1 gene have been identified in 40%–60%of human
T-ALL and 43% of human T-LBL cases, indicating that deregu-
latedNOTCH1 signaling is major contributor to the pathogenesis
of both types of T-lymphoblastic malignancies (Weng et al.,
2004; Ferrando et al., 2002; Ferrando, 2009; Park et al., 2009;
Pear and Aster, 2004; Shimizu et al., 2007; Weng et al., 2006;
Palomero et al., 2006; Sharma et al., 2006). SinceMYC activates
both cell proliferative and apoptotic pathways, tumor cells
acquire additional genetic lesions to escape cell death (Meyer
et al., 2006; Dang et al., 2005; Asker et al., 1999; Vousden,
2002). Either inactivation of the p53 pathway or overexpression
of Bcl-2 can cooperate with Myc to induce lymphomagenesis
in mice (Nilsson and Cleveland, 2003; Hoffman et al., 2002;
Pelengaris et al., 2002; Strasser et al., 1990; Eischen et al., 1999).
To identify the critical molecular changes that distinguish
T-LBL from T-ALL, we used a zebrafish model to study the fate
of transformed thymocyte progenitors. In this system, the vast
majority of transgenic fish develop T-LBL progressing rapidly354 Cancer Cell 18, 353–366, October 19, 2010 ª2010 Elsevier Inc.to T-ALL (Feng et al., 2007), analogous to cases of human
T-ALL that present with both a mediastinal mass and high
numbers of circulating lymphoblasts. In this report, we exploit
this zebrafish model to reveal genetic differences between
T-LBL and T-ALL and to uncover the underlying cellular and
molecular basis for the divergent clinical pathologies of human
T-LBL localized to the mediastinum compared with widely
disseminated human T-ALL.
RESULTS
Bcl-2 Accelerates the Onset of Myc-induced T-LBL
in Zebrafish
To determine whether bcl-2 overexpression accelerates the
development of Myc-induced T-LBL/ALL in our zebrafish model,
we bred double-transgenic (rag2-LDL-EGFP-mMyc;rag2-EGFP-
bcl-2) heterozygotes with zebrafish transgenic for Cre regulated
by the heat shock protein 70 promoter (hsp70-Cre) and then
monitored disease onset for 129 days after inducing Cre expres-
sion in the progeny. Despite their similar levels of Myc protein
(Figure S1A), the triple-transgenic fish (Myc;Cre;bcl-2) devel-
oped T-LBL earlier and with a higher penetrance than did their
siblings, which expressed only Myc;Cre: mean latency, 76 ± 27
(SD) days versus 103 ± 17 days (p < 0.0001; Figure 1A).
By 129 days of life, 78% of the triple transgenics but only 37%
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ure 1A). Furthermore, when premalignant GFP-positive T cells
were assayed by Annexin V staining, we found that bcl-2 expres-
sion did indeed inhibit apoptosis in these T cells (Figure S1B),
providing a mechanism through which bcl-2 collaborates with
Myc in lymphomagenesis.
Progression of Myc-Induced T-LBL Is Inhibited by Bcl-2
Overexpression
Althoughbcl-2 overexpression strikingly accelerated the onset of
Myc-induced T-LBL with invasion into local structures (Figures
1A and 1F), progression of the thymic lymphomas to dissemi-
nated leukemias was inhibited in these transgenics (Figures 1B
and 1F–1H), compared with the Myc-only line (Figures 1B–1E).
By 261 days of life, only 24% of the Myc;Cre;bcl-2 fish with
T-LBL had shown progression to T-ALL, in marked contrast to
the nearly 100% rapid dissemination rate in fish that expressed
only EGFP-mMyc (p = 0.0002; Figures 1B, 1D–1E, and 1G–1H).
To further explore the differences in dissemination rates, we
transplanted equal numbers of GFP-sorted control thymocytes
or lymphoma/leukemic cells intraperitoneally into irradiated
wild-type recipients. While nontransformed control rag2-EGFP-
bcl-2 thymocytes did not survive transplantation (data not
shown), both Myc;Cre and Myc;Cre;bcl-2 tumor cells were
readily transplantable, as shown by EGFP-labeled tumor cells
in the abdomens of fish at 2 weeks posttransplantation (Figures
1I and 1K). T-LBL cells from most Myc;Cre;bcl-2 transgenics
remained localized in the abdomens of transplanted recipients
and did not metastasize to other regions (Figure 1L), while the
transplanted Myc;Cre tumor cells showed widespread dissemi-
nation by 6 weeks posttransplantation (Figure 1J).
Bcl-2-Overexpressing Lymphomas Are Defective
in Vasculature Intravasation
To further examine the different fates of Myc;Cre versus
Myc;Cre;bcl-2 tumor cells in vivo, we studied tissues from sacri-
ficed fish. The rag2-GFP fish were sectioned as controls and
stained with hematoxylin and eosin (H&E). The control group
showed thymocytes residing in the thymus, without local inva-
sion into the gills or other perithymic structures (Figures 2A,
2E, and 2I). By contrast, both young (Figures 2B and 2F) and
old (Figures 2C and 2G) Myc;Cre;bcl-2 fish showed extensive
local infiltration into the gill structures, operculum, and other
regions surrounding the thymus, a finding confirmed by immu-
nostaining for GFP (data not shown). Interestingly, the malignant
Myc;Cre;bcl-2 lymphoblasts extended from the thymus along
subepithelial interstitial spaces, but they failed to invade the
vasculature and were not evident in the nearby red blood cell-
containing capillaries of the gills (Figures 2J and 2K). InMyc;Cre
fish several months of age, lymphoblasts extensively invaded the
perithymic region surrounding the gills (Figures 2D, 2H, and 2L),
including the central capillary network within the secondary gill
lamellae (Figure 2L). As we have reported (Langenau et al.,
2003), these cells were also widely disseminated and invaded
the tissues in organ systems throughout the fish, including non-
hematopoietic tissues such as distant muscle, liver, intestine,
and testis. Taken together, these results indicate that the
Myc;Cre;bcl-2 tumor cells arising in themajority of the transgenic
fish are impaired in their ability to disseminate into the vascularCsystem from the thymus, although they are locally invasive and
disseminate by extension through contiguous interstitial spaces
around the thymus.
To further elucidate how bcl-2-overexpressing lymphoma
cells disseminate by invasion across tissue planes without
intravasating into the microvasculature, we monitored the
in vivo behavior of lymphoma cells isolated from Myc;Cre and
Myc;Cre;bcl-2 transgenic zebrafish, by combining transplanta-
tion assays with in vivo confocal imaging. Due to the incomplete
excision of the loxp-dsRED2-loxp cassette from the Myc (rag2-
Loxp-dsRED2-Loxp-EGFP-mMyc) transgene (Feng et al., 2007),
cells from Myc;Cre and Myc;Cre;bcl-2 tumors both express
dsRED2 together with EGFP. The presence of dsRED2 allowed
the visualization of these tumor cells within the context of adult
host fli1-EGFP;Casper fish, which are transparent and express
EGFP much stronger in the vasculature than do the tumor cells,
allowing lymphoma cell intravasation to be monitored in vivo.
When equal numbers of FACS-sorted Myc;Cre or Myc;Cre;
bcl-2 T-LBL cells were transplanted into fli1-EGFP;Casper fish,
tumor cells were readily apparent at 6 days posttransplantation
and were assayed by confocal microscopy for dissemination
and vascular intravasation. At that time, many more Myc;Cre
tumor cells relative to Myc;Cre;bcl-2 T-LBL cells had invaded
blood vessels (Figures 2M–2R), despite the fact that most of
the latter cells were in close proximity to the vessels (Figures
2P–2R). To quantify this effect, we calculated the percentages
of intravasating Myc;Cre;bcl-2 and Myc;Cre lymphoma cells:
mean 0.56 ± 0.80 (SD) versus 1.66 ± 0.99, respectively (n = 17
and 20; p < 0.0001). Unlike the majority of transplanted Myc;
Cre;bcl-2 tumor cells, those expressing Myc;Cre circulated in
blood vessels throughout the animal at 12 days posttransplanta-
tion and were associated with a large tumor burden. Although
difficult to quantify, the transplanted Myc;Cre;bcl-2 T-LBL cells
also showed increased formation of cellular aggregates (see
Figures 2Q and 2R).Zebrafish T-LBL Cells Overexpressing Bcl-2 Undergo
Autophagy
To further examine the difference in lymphoma cells with or
without bcl-2 overexpression, we compared the morphology
and cell-cycle status of GFP-sorted thymocytes from (1) GFP
control (rag2-GFP), (2) bcl-2 control (rag2-EGFP-bcl-2), (3)
Myc;Cre;bcl-2, and (4) Myc;Cre transgenic fish (Figures
S2A–S2D). The malignant thymocytes expressing the rag2-
EGFP-bcl-2 transgene were smaller than cells transformed by
the Myc transgene alone (Figures S2C, S2D, and S7N). More-
over, cell-cycle analysis revealed that T-LBL cells from the
Myc;Cre;bcl-2 transgenic fish had a much lower proliferative
fraction (0.65% in S-phase) compared with control GFP
(9.31%), bcl-2 (10.27%) thymocytes or with tumor cells from
the Myc;Cre transgenic fish (10.8%) (Figure S2E). These char-
acteristics could reflect metabolic stress and autophagy, so
Myc;Cre and Myc;Cre;bcl-2 lymphoma cells were assessed
by transmission electron microscopy. Interestingly, T-LBL cells
overexpressing bcl-2 had significantly more autophagosomes/
autolysophagosomes than Myc;Cre tumor cells: 2.7 ± 2.0
(SD) versus 0.23 ± 0.58 per cell section (p < 0.0001; Figures
3A–3E).ancer Cell 18, 353–366, October 19, 2010 ª2010 Elsevier Inc. 355
Figure 2. Zebrafish T-Lymphoblasts Overexpressing Bcl-2 Spread Locally but Fail to Intravasate into Vasculature
(A, E, and I) T cells in a control fish are restricted to the thymus above the gill arches and underneath the operculum (n = 3).
(B, C, F, G, J, and K) GFP and dsRED2-positive tumor cells (arrowheads; F,G) in the Myc;Cre;bcl-2 fish invade tissues outside the thymus and infiltrate local
structures, including the primary lamellae (filaments) and cartilaginous gill rays by 2 months (B, F, and J; n = 3) but fail to invade vasculature by 10 months
(C, G, and K; n = 3).
(D, H, and L) By contrast, GFP- and dsRED2-expressing cells of theMyc;Cre transgenic fish (D, H, and L; n = 3) enter secondary lamellae that contain the capillary
network (compare J and K with L, arrows) and disseminate widely throughout the host, infiltrating distant muscle and fat tissues by 6 months.
(M, N, and O) dsRED2-expressing lymphoma cells (N) from the Myc;Cre fish intravasate into EGFP-labeled vasculature (M) of the transplant host (fli1-EGFP;-
Casper) by 6 day posttransplantation (see arrowheads in O).
(P, Q, and R) In contrast, dsRED2-expressing lymphoma cells (Q) from theMyc;Cre;bcl-2 fish fail to intravasate vasculature (P) of the transplant hosts by 6 day
posttransplantation (compare R with O). Note aggregates of theMyc;Cre;bcl-2 lymphoma cells in Q and R. Black arrowhead in (A) points to thymus (T) and the gill
region is indicated (G). Inserts in (F)–(H) show enlargements of tumor cells. Scale bar for (A)–(D), 200 mm; for (E)–(H) 50 mm; for (I)–(L) and (M)–(R), 10 mm.
See also Figure S2.
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a marker for autophagy (Kabeya et al., 2000) and its active form,
Lc3-II, was abundant in Myc;Cre;bcl-2 lymphoma cells but not
in Myc;Cre lymphoma cells (Figure 3F). Myc;Cre tumors also
failed to express the precursor form, Lc3-I, consistent with the
LC3 gene being transcriptionally upregulated only when cells
undergo autophagy (Donati et al., 2008; Yasmeen et al.,
2003). These findings show that autophagy is triggered as
a catabolic survival mechanism specific toMyc;Cre;bcl-2 tumor
cells.356 Cancer Cell 18, 353–366, October 19, 2010 ª2010 Elsevier Inc.To test whether autophagy contributed to the inability
of zebrafish bcl-2-overexpressing lymphoma cells to dissemi-
nate, we treated control wild-type fish, and Myc;Cre and
Myc;Cre;bcl-2 transgenic fish with the autophagy inhibitor chlo-
roquine (CQ), which was well-tolerated by both wild-type and
tumor-bearing fish at a concentration up to 100 mM. As expected
(Amaravadi et al., 2007), autophagosomes/autolysosomes
could not metabolize their contents, resulting in their signi-
ficantly increased numbers in CQ-treated T-LBL cells compared
with controls (mean: 17.9 ± 10.7 [SD] versus 5.8 ± 3.8,
Figure 3. Zebrafish Lymphoblasts Overexpressing Myc and Bcl-2 Undergo Autophagy
(A) Electron microscopic analysis rarely identified autophagosomes in tumor cells from Myc;Cre transgenic fish. Mitochondria are indicated by arrows.
(B–D) Thymic lymphoblasts fromMyc;Cre;bcl-2 triple-transgenics show prominent autophagosomes/autolysophagosomes. (C) is a magnified view of (B) (box).
Arrows indicate double-membrane autophagosomes containing cytoplasm and cytoplasmic organelles. An autolysophagosome is shown in (D) (arrow).
(E) Quantification of autophagosomes and autolysophagosomes inMyc;Cre (solid bars) andMyc;Cre;bcl-2 (hatched bars) tumor cells were harvested from three
individual fish. From 9 to 15 different cells from each fish were sectioned and analyzed. Mean ± SD results from three individual fish are shown.
(F) Western blot analyses of the protein levels of EGFP-zbcl-2, Lc3-I, and Lc3-II in three individualMyc;Cre andMyc;Cre;bcl-2 transgenic fish. Actin was used as
a loading control in each lane.
Scale bars for (A)–(D), 500 nm.
See also Figure S3.
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in Myc;Cre;bcl-2 fish disseminated over 12 weeks of treatment
with CQ (Figures S3F–S3I), indicating that autophagy is not
responsible for the lack of T-LBL cell dissemination.
AKT Activation Promotes the Progression of T-LBL
to T-ALL in Zebrafish
AKT activation by phosphorylation is known to promote T cell
migration and nutrient uptake, to relieve metabolic stress, and
to suppress autophagy (Sotsios and Ward, 2000; Lum et al.,
2005), suggesting its involvement in the progression of T-LBL
to T-ALL. We therefore examined the levels of phospho-Akt
(Ser473p-Akt) in lymphoma cells in two separate experiments
with (1)Myc;Cre;bcl-2 transgenic fish in which tumors remained
localized as T-LBL (n = 5); (2) leukemic cells from the 24% of
Myc;Cre;bcl-2 fish in which the cells disseminated as T-ALL
(n = 6); and (3) leukemic cells expressing Myc;Cre alone (n = 6;
Figure 4A; data not shown). In both experiments, there were
striking increases in Ser473p-Akt, indicating elevated levels of
phosphorylated Akt in Myc;Cre;bcl-2 tumors that had dissemi-
nated as T-ALL. This was in marked contrast to the low levels
of Ser473p-Akt observed in T-LBL tumor cells that remained
confined locally around the thymus. Levels of Ser473-p-Akt
and Lc3-II (Figure 4A, lanes 6–8) were consistently low in the
Myc;Cre leukemic cells, suggesting that Akt activation was not
required by these tumor cells to promote intravasation and
dissemination.
To test experimentally whether Akt activation can promote the
progression of T-LBL to T-ALL, we introduced a constitutivelyCactive, myristoylated murine Akt2 (Myr-Akt2) transgene driven
by the rag2 promoter into the Myc;Cre;bcl-2 transgenic fish by
microinjection at the 1-cell stage. Tumor cells from all four fish
tested with constitutive expression of Myr-Akt2 had increased
Ser473p-Akt levels, as did one of the four fish without Myr-Akt2
expression (Figure 4B). Constitutively activated Akt promoted
more rapid onset of T-LBL in the Myc transgenic fish with or
without bcl-2 overexpression (Figure S4), and more rapid
dissemination of T-LBL to T-ALL in the Myc;Cre;bcl-2;Myr-Akt2
transgenic fish (Figures 4E–4G). By 217 days of life, 85% of the
Myc;Cre;bcl-2;Myr-Akt2 transgenic fish with T-LBL had devel-
oped T-ALL, in marked contrast to only 30% of the
Myc;Cre;bcl-2 transgenic fish with T-LBL (Figure 4G). Dissemi-
nation was more rapid, as the earliest time that the
Myc;Cre;bcl-2;Myr-Akt2 transgenic fish developed T-ALL was
34 days of life, compared with 114 days for their Myc;Cre;bcl-2
siblings.
Human T-LBL Cells Undergo Autophagy
To test whether human T-LBL, but not T-ALL, lymphoblasts
undergo autophagy, as predicted by our zebrafish model, we
performed western blot analysis to examine expression of the
autophagy protein LC3-I and its active LC3-II isoform (Kabeya
et al., 2000; Donati et al., 2008; Yasmeen et al., 2003). Relative
to the T-ALL cases, the T-LBL cases showed high levels of
LC3-I and LC3-II (Figure 5A), indicating that human T-LBL
lymphoblasts were actively undergoing autophagy. We
confirmed this finding by demonstrating higher levels of another
protein indicative of autophagy, BECLIN 1 (ATG6) (Cao andancer Cell 18, 353–366, October 19, 2010 ª2010 Elsevier Inc. 357
Figure 4. Akt Activation Promotes the Progression of T-LBL to T-ALL in Myc;Cre;bcl-2 Transgenic Fish
(A) Western blot analysis of Lc3-I, Lc3-II, Ser473p-Akt, and Akt protein expression in zebrafishMyc;Cre;bcl-2 lymphoma (two tumor samples) and leukemia (three
tumor samples) cells and in zebrafish Myc;Cre leukemia cells (three tumor samples).
(B) Western blot analysis of Ser473p-Akt and Akt expression in Myc;Cre;bcl-2 (n = 4) and Myc;Cre;bcl-2;Myr-Akt2 (n = 4) zebrafish lymphomas.
(C–F) Upon constitutive activation of Myr-Akt2, Myc;Cre;bcl-2 transgenic fish rapidly progress from T-LBL (E; T-LBL onset at 20 days) to T-ALL (F; at 34 days),
compared with the Myc;Cre;bcl-2 transgenic fish lacking Myr-Akt2 expression (C and D).
(G) Rate of T-LBL progression to T-ALL inMyc;Cre;bcl-2 transgenic fish (n = 10; red) andMyc;Cre;bcl-2;Akt2 transgenic fish (n = 20; purple). Actin protein levels in
(A) and (B) served as loading controls. Scale bars for (C)–(F), 1 mm.
See also Figure S4.
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BCL2, S1P1, and ICAM1 in T-LBL ProgressionKlionsky, 2007), which is transcriptionally upregulatedwhen cells
undergo autophagy (Donati et al., 2008; Cao and Klionsky, 2007;
Yan et al., 2007), in T-LBL compared with T-ALL samples
(Figure 5A). In autophagic cells, the LC3-II isoform is seques-
tered in autophagosomes, allowing its subcellular localization
to be detected by immunofluorescence assays (Kabeya et al.,
2000). LC3 was expressed at low diffuse levels in the cytoplasm
of normal T cells (Figures 5G and 5J) and of the lymphoblasts in
10 of 11 T-ALL bone marrow samples (Figures 5I and 5L;
Figure S5C). However, strong punctate LC3 staining was
observed in seven of nine T-LBL cases examined (Figures 5H
and 5K; Figure S5C), further supporting subcellular sequestra-
tion of LC3 and the specific induction of autophagy in human
T-LBL but not T-ALL lymphoblasts.Human T-LBL Cells Overexpress BCL2a, S1P1,
and ICAM1
Our zebrafish data suggest that a difference in BCL2 expression
may represent an important distinction between human T-LBL
and T-ALL. The human BCL2 protein has two isoforms that are
produced by alternatively spliced transcripts. The widely studied
antiapoptotic BCL2a isoform contains 239 amino acids and
a hydrophobic carboxy-terminal transmembrane domain (TM)
(Figure S5A). This membrane anchor is lacking in the 205 amino
acid BCL2b isoform (Figure S5A), which appears to lack
antiapoptotic activity (Tanaka et al.,1993). The zebrafish bcl-2
transgene used in this study is most similar to the human
BCL2a isoform.358 Cancer Cell 18, 353–366, October 19, 2010 ª2010 Elsevier Inc.To determine whether BCL2a is differentially expressed in
primary human T-LBL and T-ALL cells, we analyzed recently
published RNA expression profiling results obtained from nine
T-LBL and ten T-ALL samples (Raetz et al., 2006). Expression
of BCL2a in human T-LBL was significantly higher than that in
T-ALL (Figure 5C; Table S1). To determine if T-LBL samples
had higher BCL2a protein levels, we extracted proteins from
six T-LBL and seven T-ALL primary patient samples and
subjected them to western blot analysis. The Du528 T-ALL cell
line, which expresses both BCL2a and BCL2b was used as
a control to show the relative migration of the two isoforms (Fig-
ure S5B). Analysis of this western blot (Figure S5B) showed that
BCL2a levels were significantly higher (p = 0.038) in T-LBL
versus T-ALL samples (BCL2a/ACTIN ratio mean: 0.29 ± 0.07
[SD] versus 0.09 ± 0.02; Figure 5D), while there were no detect-
able differences in the expression levels of other antiapoptotic
proteins, such as MCL1 and BCLXL (Figure 5A; Table S1).
To extend our analysis of BCL2 expression in lymphoblastic
lymphoma cells, we performed immunohistochemical analyses
of normal and T-LBL human thymic tissue biopsies, together
with T-ALL specimens from bone marrow biopsies (Figure 6).
While both T-LBL and T-ALL samples contained mature T cells
with strong BCL2 expression, the normal thymic architecture in
the T-LBL samples was clearly disrupted, and 7 of 11 of these
samples showed high levels of BCL2 expression in the tumor
cells (Figures 6B and 6E; Figure S6). By contrast, BCL2 levels
were essentially undetectable in the lymphoblasts from 10 of
11 T-ALL samples (Figures 6C and 6F). Our analysis demon-
strates that BCL2 levels are significantly higher in human
Figure 5. Human T-LBLs Undergo Autophagy and Overexpress BCL2a, S1P1, and ICAM1
(A) Western blot showing protein levels of MCL1, BCLXL, BCL2a, LC3-I, LC3-II, BECLIN 1, S1P1, and ACTIN in six T-LBL versus six T-ALL human patient
samples.
(B) Western blot showing the levels of ICAM1, LFA1, E-Cad, N-Cad, CD99, and ACTIN in six T-LBL versus six T-ALL human patient samples.
(C) Gene expression profiling of human T-LBL and T-ALL samples shows that BCL2a is expressed at high levels in T-LBL but not T-ALL samples.
(D) BCL2a versus ACTIN protein ratios demonstrating that BCL2a levels are significantly higher in human T-LBL samples compared with T-ALL samples (n = 6 for
T-LBL and n = 7 for T-ALL; to view the western blot, see Figure S5B).
(E) S1P1 versus ACTIN protein ratios demonstrating that S1P1 protein levels are significantly higher in human T-LBL samples compared with T-ALL samples.
(F) ICAM1 versus ACTIN protein ratios demonstrating the significantly higher ICAM1 in human T-LBL samples compared with T-ALL samples.
(G–I) Immunofluorescent staining indicates the subcellular localization of LC3 in normal thymus (G), T-LBL (H), and T-ALL (I) cells.
(J–L) DAPI staining of the cells shown in (G)–(I), respectively.
AU stands for arbitrary units. Bars denote median values.
Scale bars for (G)–(L), 10 mm.
See also Figure S5 and Table S1.
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Figure 6. Immunohistochemical Analysis of BCL2 and S1P1 in Human T-LBL and T-ALL
(A–F) Human BCL2 detected by immunohistochemistry in normal thymus (A and D) and in samples from patients with T-LBL (B and E) or T-ALL (C and F). (D)–(F)
are magnified views of boxes in (A)–(C), respectively, and insets show individual cells including a mature thymocyte with high BCL2 expression.
(G–L) Human S1P1 detected by immunohistochemistry in normal thymus (G,J) and in samples from patients with T-LBL (H and K) and T-ALL (I and L). (J)–(L) are
magnified views of boxes in (G)–(I), respectively. Note the reciprocal expression pattern of BCL2 and S1P1 in the thymic cortex and medulla regions. The thick
arrows in (A) and (G) show the thymic medulla region, while thin arrows in (D)–(F) indicate mature thymocytes with high BCL2 expression. Arrowheads in (J)–(L)
show the S1P1 expression on the cortical thymocytes or lymphoblasts.
Scale bars for (A)–(C) and (G)–(I) = 0.5 mm; (D)–(F) and (J)–(L), 50 mm. See also Figure S6 and Table S2.
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consistent with the predictions of our zebrafish model. To
address whether the difference in BCL2 levels between T-LBL
and T-ALL might reflect altered stages of T cell development,
we performed immunohistochemical assays of the CD3, CD4,
and CD8 surface antigens but did not identify any differences
in the patterns of expression between these two disease types
(see Table S2).
Although increased expression of BCL2 in T-LBL cells may
contribute to the onset of lymphoma, it does not explain why in
many of these cases the transformed cells fail to invade the
vasculature and disseminate. To address this question, we
analyzed the published gene expression data of Raetz and
coworkers using Gene Set Enrichment Analysis (GSEA) to see
if the curated gene sets for integrin mediated cell adhesion,
cell adhesion molecules and leukocyte transendothelial migra-
tion were differentially expressed in T-LBL versus T-ALL (Raetz360 Cancer Cell 18, 353–366, October 19, 2010 ª2010 Elsevier Inc.et al., 2006; Mootha et al., 2003). Although GSEA analysis failed
to reveal significant enrichment for any of these three gene sets
(http://www.broadinstitute.org/gsea/msigdb/index.jsp) between
T-LBL (n = 9) and T-ALL (n = 10) patient samples, some individual
genes within these gene sets did exhibit differential expression.
After including additional candidate genes reported in the litera-
ture, we focused our efforts on six proteins involved with
T-lymphocyte adhesion and migration, which included S1P1,
ICAM1 (the downstream target of S1P1), and its receptor
LFA1, E2 (CD99), N-cadherin, and E-cadherin (Petrie and
Zu´n˜iga-Pflu¨cker, 2007; Rosen and Goetzl, 2005; Makgoba
et al., 1988; Bernard et al., 1995; Kawamura-Kodama et al.,
1999). While our western blot analysis failed to detect significant
differences in the expression levels of four of the six molecules
tested, significant increases in S1P1 and ICAM1 levels were
observed in T-LBL relative to T-ALL cells: S1P1/ACTIN ratio,
mean 2.96 ± 1.90 (SD) versus 0.77 ± 1.19, p = 0.04 (Figures 5A
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BCL2, S1P1, and ICAM1 in T-LBL Progressionand 5E); ICAM1/ACTIN ratio, mean 1.67 ± 0.96 (SD) versus
0.07 ± 0.09, p = 0.007 (Figures 5B and 5F). These results are
interesting because S1P1 signaling promotes homotypic T cell
adhesion and inhibits thymocyte emigration and endothelial
intravasation, at least in part through S1P1’s ability to upregulate
ICAM1 levels (Makgoba et al., 1988; Rosen et al., 2009; Lin et al.,
2007).
To extend our western blot results to additional cases, we
examined S1P1 expression levels by immunohistochemical
analysis of normal thymus, T-LBL tumor biopsies, and T-ALL
bone marrow biopsies. As shown in Figures 6A and 6D, BCL2
is normally not detectable in immature thymocytes in the thymic
cortex and then is markedly upregulated to promote the survival
of more mature single-positive thymocytes in the medulla
that are ready to egress via the circulation. By contrast, S1P1
is expressed by cortical thymocytes and is downregulated
as more mature thymocytes traffic to the medulla (Figures 6G
and 6J). In the T-LBL cases, S1P1 is expressed at levels
comparable to the high levels normally expressed by immature
cortical thymocytes that are retained in the thymus (Figures 6H
and 6K; Figure S6; Table S2), while BCL2 levels are aberrantly
upregulated similar to more mature thymocytes in the thymic
medulla (Figures 6B and 6E; Table S2). By contrast, only a small
subset T-ALL cells expressed detectable levels of S1P1
(Figures 6I and L; Figure S6; p = 0.03). These results show
that the high S1P1 levels observed on human T-LBL cells
most closely resemble the levels that found on immature nor-
mal cortical thymocytes that are retained in the thymus, while
human T-ALL lymphoblasts with low S1P1 levels resemble
those that are able to emigrate from the thymus into the
circulation.
Bcl-2-Overexpressing T-LBL Cells Exhibit Increased
Aggregation that Can Be Overcome by Akt Activation
or S1P1 Inhibition
To gain further insight into the failure of T-LBL cells to dissemi-
nate in Myc;Cre;bcl-2 transgenic fish, we analyzed the pheno-
typic behavior of these sorted tumor cells in vitro. Tumor cells
from both Myc;Cre and Myc;Cre;bcl-2 transgenic fish were
unable to survive in vitro without the support of a zebrafish
kidney stromal cell line (ZKS) (Stachura et al., 2009; data not
shown). Growing on a monolayer of ZKS cells, T-LBL cells over-
expressing bcl-2 andMyc survived far better than did their coun-
terparts overexpressing Myc alone, under both normal and
hypoxic conditions. Compared with T-LBL cells overexpressing
Myc alone, which die by 12 days in culture, T-LBL cells overex-
pressing bcl-2 and Myc can routinely survive for over 2 months.
The Myc;Cre;bcl-2 lymphoma cells were significantly smaller
thanMyc;Cre cells under both normal (mean ± SD cell diameter,
1.79 ± 0.59 mm versus 3.33 ± 1.50 mm) and hypoxic (1.62 ± 0.55
mm versus 3.30 ± 1.46 mm) conditions (p < 0.0001, Figure S7N),
consistent with their autophagic state, which may promote their
survival under both in vivo and in vitro conditions. Myc;Cre cells
appeared large and apoptotic, expressed the apoptotic marker
Annexin V on their surface (Figure S7P) and were noticeably
less healthy after 8 days in culture, particularly under hypoxic
conditions (Figure S7L). These observations demonstrate that
Myc;Cre;bcl-2 T-LBL cells have a survival advantage over
Myc;Cre cells.CInterestingly, when cultured in vitro, single FACS-sorted
lymphoma cells from the majority of Myc;Cre;bcl-2 transgenic
fish formed aggregates (over ten cells per aggregate) in standard
(Figures 7C and 7F) aswell as hypoxic (Figure S7F) culture condi-
tions. In contrast, malignant cells from all Myc;Cre transgenic
fish failed to form aggregates under the same conditions (Figures
7B and 7F). The number ofMyc;Cre;bcl-2 T-LBL cell aggregates
increased over time and was not dependent upon initial plating
densities (Figures S7A–S7E and S7M), compared with Myc;Cre
lymphoma cells (Figure S7G–S7K). Furthermore, the numbers
of viable lymphoma cells did not significantly increase over
a week in culture (Figure S7O), indicating that the formation
and increased numbers of aggregated Myc;Cre;bcl-2 T-LBL
cells was not due to increased proliferation. These cells survived
over 2 months in vitro and still retained the ability to aggregate
(data not shown).
To examine whether the T-LBL aggregation phenotype could
be overcome by Akt activation, we cultured tumor cells from
both the 24% ofMyc;Cre;bcl-2 transgenic fish with endogenous
Akt activation that progressed to T-ALL and the Myc;Cre;bcl-
2;Myr-Akt2 transgenic fish. Importantly, leukemic cells from
most of theMyc;Cre;bcl-2 orMyc;Cre;bcl-2;Myr-Akt2 fish failed
to aggregate (Figures 7D–7F), as compared with the T-LBL cells
from the 76% of Myc;Cre;bcl-2 transgenic fish that remained
localized, indicating that Akt activation is able to overcome the
aggregating properties of Myc;Cre;bcl-2 lymphoma cells and
that the abrogation of in vitro aggregation appears to be linked
to the cells’ capacity to disseminate.
Because S1P1 was overexpressed by human T-LBL cells, and
the ligand-binding domain of zebrafish s1p1 is also highly
conserved, we tested whether the S1P1 pathway regulated the
cellular aggregation phenotype of zebrafish Myc;Cre;bcl-2
T-LBL cells, using W146, a specific S1P1 antagonist (Sanna
et al., 2006), to treat malignant cells from transgenic fish. While
W146 treatment had no detectable effect on the malignant cells
from Myc;Cre fish (data not shown), it caused a marked reduc-
tion in the aggregation of Myc;Cre;bcl-2 T-LBL cells without
affecting cell survival (Figures 7G–7K; data not shown). These
results indicate that the homotypic cell-cell aggregation of the
bcl-2-overexpressing T-LBL cells depends upon S1P1 signaling.
S1P1 Antagonist Treatment Promotes the Intravasation
of Bcl-2-Overexpressing T-LBL Cells In Vivo
To establish whether the S1P1 signaling pathway regulates the
ability of Myc;Cre;bcl-2 lymphoma cells to intravasate into the
microvasculature, we treated Myc;Cre;bcl-2 transplants in vivo
with the W146 S1P1 inhibitor (Figure 8A). Twelve days after
transplantation, either a control vehicle solution or the W146
inhibitor was injected into the host fli1-EGFP;Casper fish at the
cell transplantation site. Three days later, the fish were examined
by confocal microscopy and scored for dissemination and intra-
vasation. Minimal intravasation of the transplanted cells was
observed in the vehicle-treated fish (Figures 8B–8D), while the
W146-treated fish showed significantly higher numbers of intra-
vasating tumor cells (Figures 8E–8G; mean ± SD intravasation
score, 0.89 ± 0.83 versus 2.07 ± 0.86, respectively, p < 0.0001).
Similar to what was observed previously (Figures 2Q and 8C),
the transplanted Myc;Cre;bcl-2 T-LBL cells formed aggregates
in vivo in the control-treated fish, while the W146 treatment ledancer Cell 18, 353–366, October 19, 2010 ª2010 Elsevier Inc. 361
Figure 7. Bcl-2-Overexpressing T-LBL Cells Display Increased Aggregation that Can Be Overcome by Akt Activation or S1P1 Inhibition
In Vitro
(A) Schematic of the experimental strategy.
(B–E) Brightfield images of lymphoma or leukemic tumor cells in culture for 7 days on ZKS stroma: (B)Myc;Cre T-LBL, (C)Myc;Cre;bcl-2 T-LBL, (D)Myc;Cre;bcl-2
T-ALL, or (E) Myc;Cre;bcl-2;Myr-Akt2 T-ALL cells.
(F) Quantification of aggregates over free cells for tumor cell culture on ZKS cells under normal conditions for 7 days:Myc;Cre T-LBL (n = 10),Myc;Cre;bcl-2 T-LBL
(n = 11), Myc;Cre;bcl-2 T-ALL (n = 13), or Myc;Cre;bcl-2;Myr-Akt2 T-ALL (n = 11) transgenic fish.
(G–J) The formation of homotypic cell aggregation ofMyc;Cre;bcl-2 T-LBL cells is inhibited after treatment with a specific S1P1 antagonistW146 (1, 5, and 50 mM)
in ZKS stroma supported cell culture.
(K) Ratio of cell aggregates to free cells inMyc;Cre;bcl-2 T-LBL cells 7 days after plating on ZKS stromawith vehicle only, or increasing amounts ofW146 (n = 4 per
group) ranging from 1 to 50 mM treatment.
Bars in (F) and (K) represent means determined from independent animals, and error bars represent standard deviation of the mean.
Scale bar for panels B-E and G-J = 40 mm. See also Figure S7.
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indicate that inhibition of S1P1 signaling can restore the capacity
for Myc;Cre;bcl-2 lymphoma cells to disaggregate and intrava-
sate into the vasculature in vivo, thus implicating high S1P1 levels
in theblockade of dissemination observed in zebrafish T-LBLand
by extension in human patients with this disease.
DISCUSSION
Our studies in zebrafish define the cellular and molecular differ-
ences between human T-LBL and T-ALL, providing for a biolog-
ical basis for the different clinical presentations of these twoT cell362 Cancer Cell 18, 353–366, October 19, 2010 ª2010 Elsevier Inc.malignancies. The results indicate that aberrant overexpression
of BCL2 together with MYC accelerates the onset of malignant
transformation by suppressingMyc-induced apoptosis (Strasser
et al., 1990), while elevated S1P1 and ICAM1 levels promote
homotypic cell adhesion through binding to LFA1, associated
with a blockade of intravasation and thymic egress. The trans-
formed T-LBL lymphoblasts that are unable to intravasate and
undergo hematologic dissemination remain trapped in the
thymic region, where they proliferate to the capacity of their local
nutrient supply and induce the autophagy program in response
to metabolic stress. Conversely, MYC-stimulated lymphoblasts
with low levels of BCL2 expression appear to undergo a more
Figure 8. The Selective S1P1 Antagonist W146 Promotes Intravasation of Bcl-2-Overexpressing T-LBL Cells In Vivo
(A) Schematic drawing of the experimental strategy.
(B–G) Confocal images of EGFP-labeled blood vessels (B and E), dsRED2-labeled lymphoma cells (C and F), and the merged images of a vehicle-treated
(D; n = 29) and aW146-treated transplanted animal (G; n = 18) demonstrate that W146 treatment promotes intravasation of bcl-2-overexpressing lymphoma cells
(arrowheads) in vivo (cf. G to D). Note that W146 treatment also inhibited the in vivo formation of lymphoma cell aggregates (cf. F to C).
Scale bar for (B)–(G), 10 mM.
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activation of alternative cell survival programs, as well as molec-
ular pathways that promote dissemination outside of the thymic
environment. These T-ALL lymphoblasts rapidly undergo hema-
tologic dissemination to nutrient rich environments throughout
the host, thus avoiding metabolic stress and the induction of
autophagy.
Thymocytes express a number of adhesion molecules,
including N-cadherin, E-cadherin, ICAM1, and LFA1, during
specific stages of maturation that are associated with specific
functions including thymocyte emigration and intravasation
(Petrie and Zu´n˜iga-Pflu¨cker, 2007; Boyd et al., 1988). The regu-
lated expression of ICAM1 controls the balance of homotypic
cell-cell adhesion and heterotypic adhesion to vascular endothe-
lial cells, which modulates the intravasation process (Boyd et al.,
1988; Gares and Pilarski, 2000). Recent evidence supports the
contribution of S1P1 function to the process of thymocyte intra-
vasation through its regulation of ICAM1 levels (Lin et al., 2007),
and S1P1 agonists such as SEW2874 have been shown to
increase S1P1 signaling in the thymus and inhibit mature thymo-
cyte egress (Sanna et al., 2006). Consistent with these data, we
show that T-LBL cases overexpressing BCL-2 have high S1P1
levels mirroring those of immature cortical thymocytes that do
not emigrate from the thymus (Figure 6G). The mechanism
underlying this association is uncertain, but it does not appear
to be solely dependent on the state of thymocyte differentiation,
since cases of both T-ALL and T-LBL can present with cell
surface markers indicating arrested T cell development at allCmaturation stages (Crist et al., 1988). Our experiments also
show that the W146 S1P1 inhibitor reduces homotypic thymo-
cyte cell-cell adhesion and implicate the loss of homotypic
cell-cell adhesion in the ability of T-LBL cells to intravasate in
our in vivo transplantation assays. The evidence of elevated
S1P1 and ICAM1 expression in human T-LBL cells, together
with evidence for S1P1-dependent cell aggregation in vitro and
in vivo, strongly support a role of homotypic cell adhesion medi-
ated through elevated ICAM1, in regulating T-LBL intravasation
and subsequent hematologic dissemination.
Our results suggest that the induction of autophagy is a conse-
quence rather than a cause of the inability of malignant
T-lymphoblasts to disseminate in our zebrafish model. First,
when zebrafish Myc;Cre;bcl-2 T-LBL cells were cultured
in vitro, their survival indicated that their inability to disseminate
could not be attributed to their inability to survive outside the
thymic niche. Second, inhibitors of autophagy failed to restore
the ability of T-LBL cells to disseminate.
While low levels of activated Akt were observed in
Myc;Cre;bcl-2 zebrafish with localized T-LBL lymphomas, the
Myc;Cre;bcl-2 lymphomas that progressed to T-ALL possessed
high levels of phospho-Akt (Ser 473-p-Akt), suggesting that AKT
activation provides a mechanism allowing bcl-2-overexpressing
cells to disseminate. Furthermore, the expression of a constitu-
tively active form of murine Akt2 (Myr-Akt2) in Myc;Cre;bcl-2
transgenic zebrafish promoted rapid dissemination of the
disease while lymphoblasts overexpressing Akt failed to aggre-
gate in vitro, further supporting the association betweenancer Cell 18, 353–366, October 19, 2010 ª2010 Elsevier Inc. 363
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BCL2, S1P1, and ICAM1 in T-LBL Progressionactivated Akt signaling, the loss of cell adhesion and T-ALL
dissemination.
Human T-ALL and T-LBL are considered to represent different
clinical presentations of the same disease that are often treated
with identical treatment regimens. Our studies suggest that
different molecular and cell biologic properties may render these
diseases uniquely susceptible to different types of targeted ther-
apies. Thus, in T-LBL patients, combination of BCL2 and AKT
inhibitors could promote lymphoblast death while blocking path-
ways that lead to lymphoblast escape and dissemination. Such
approaches would likely have little efficacy for the majority of
patients with T-ALL, who have low levels of BCL2 expression
and lack evidence of activation of autophagy. Our studies also
suggest that BCL2 levels, AKT phosphorylation, and LC3 and
BECLIN1 levels should be carefully analyzed in future clinical
trials, to determine whether these biomarkers predict clinical
response and implicate pathways for targeted therapy.
EXPERIMENTAL PROCEDURES
Fish Husbandry
Zebrafish husbandry was performed as described (Westerfield, 1994) in the
Dana-Farber zebrafish facility, in accord with our ACUC-approved protocol.
Overexpression of Myc, bcl-2, and Myr-Akt2 in Zebrafish
Lymphocytes, Tumor Screen, and Fish Genotyping
To test the cooperative effect of bcl-2 and mMyc, we bred double-transgenic
fish, rag2-EGFP-bcl-2;rag2-LDL-EGFP-mMyc, to homozygous hsp70-Cre
fish. To overexpress Myr-Akt2 in lymphocytes, we injected the ISceI-Rag2-
Myr-Akt2-ISceI construct with the I-SceI meganuclease into one-cell-stage
embryos from the same breeding scheme described above. All resulting
progeny were heat-shocked and raised, monitored for T-LBL onset and gen-
otyped as described (Feng et al., 2007). Thymocytes were dissected for
DNA extraction and genotyped from fish injected with the ISceI-rag2-Myr-
Akt2-ISceI construct. Genotyping primer information is included in Supple-
mental Experimental Procedures.
Analysis of Zebrafish Lymphoma and Leukemic T cells
Control (from rag2-GFP and rag2-EGFP-bcl-2) or transformed T cells (from
Myc;Cre, Myc;Cre;bcl-2 or Myc;Cre;bcl-2;Myr-Akt2) were collected under
a UV-dissection scope (Leica) and sorted on the basis of dsRED2/GFP expres-
sion. The sorted cells were subjected to (1) transplantation into recipients
(0.7 million cells per fish) as described (Langenau et al., 2005); (2) electron
microscopic analysis to determine the presence and number of autophago-
somes and autolysophagosomes per cell section (9–15 different cell sections
were obtained for eachMyc;Cre and Myc;Cre;bcl-2 fish); or (3) in vitro culture
to assay aggregation properties (see Supplemental Experimental Procedures
for details).
Small Molecule Treatment and Confocal Imaging
The S1P1 antagonist W146 or the control vehicle was added to the cultured
dsRED2/GFP-sorted lymphoma cells and cell aggregation was assayed as
described in the Supplemental Experimental Procedures section. For in vivo
treatment, W146 or vehicle was injected into the host fli1-EGFP;Casper fish
that had received Myc;Cre;bcl-2 lymphoma cells. Transplant recipients were
examined for EGFP (blood vessels) and dsRED2 (tumor cells) by confocal
imaging. Each image was scored on a 0–3 scale that estimated the fraction
of tumor cells contained within a blood vessel, as follows: 0 = no cells in blood
vessels, 1 =%25% of cells in blood vessels, 2 = 25%–75% in blood vessels,
and 3 = 100% in blood vessels.
Patient Samples
Diagnostic bonemarrow specimenswere collectedwith informed consent and
with approval of the Dana-Farber Cancer Institute Institutional Review Board
from children with T-ALL enrolled in Dana-Farber Cancer Institute clinical trials364 Cancer Cell 18, 353–366, October 19, 2010 ª2010 Elsevier Inc.for pediatric ALL. T-LBL diagnostic specimens were removed at surgery from
patients diagnosed at Children’s Hospital Boston who gave informed consent
for use of anonymized surgical specimens for research purposes after all clin-
ically relevant evaluations were performed, with approval of the Children’s
Hospital Boston Institutional Review Board. All samples are reported by arbi-
trary Sample ID numbers without linked identifiers (Table S2) and were
analyzed with approval of the Dana-Farber Cancer Institute Institutional
Review Board. Mononuclear tumor cells were isolated from T-ALL bone
marrow specimens by Ficoll-Hypaque density centrifugation. The diagnosis
of T-ALL or T-LBL was made by each institution’s pathologists and clinicians
based on criteria of the World Health Organization.
Western Blot Analysis
The primary antibodies included anti-BCL2, anti-CD3, anti-CD4, and anti-CD8
(Santa Cruz), anti-BCLXL (BD Biosciences), anti-MCL1 (BD Biosciences), anti-
LC3 (MBL International Co.), anti-LC3b (Abcam), anti-BECLIN1 (ANASPEC
Inc.), anti-S1P1 (Novus Biologicals), anti-AKT, anti-phosph Ser473-AKT,
anti-ICAM1, anti-N-cadherin, anti-E-cadherin (Cell Signaling), anti-LFA1 (Life-
Span Biosciences), anti-CD99 (Invitrogen), and anti-ACTIN (Sigma) antibodies.
Secondary antibodies included horseradish peroxidase-conjugated anti-
mouse or anti-rabbit antibodies (Pierce). Autoradiographs were either exposed
directly to CL-exposure film (Pierce) and then scanned with a MICROTEK
Deskscan or were imaged with a G:BOX chemi HR16 device (Syngene) and
aCCDcamera, and then subjected to analysiswithSyngenegenetool software.
Immunohistochemistry and Immunofluorescence Staining
See Supplemental Experimental Procedures for detailed descriptions.
Statistical Analysis
Kaplan-Meier analysis and the log-rank test were used to compare times to
T-LBL or T-ALL onset among groups of fish. The exact Wilcoxon rank-sum
statistic was used to compare aggregates over free cells among lymphoma
and leukemic cells from different transgenic fish. Fisher’s exact test was
used to analyze differences in BCL2a, LC3, and CD3/CD4/CD8 staining in clin-
ical samples of T-LBL versus T-ALL lymphoblasts. Student’s t test was used to
analyze differences in EGFP-mMyc levels, annexin V positive cells, S-phase
cells, cell size, autophagosome number in Myc;Cre versus Myc;Cre;bcl-2
tumor cells, control- or chloroquine-treated Myc;Cre;bcl-2 tumor cells, the
BCL2/ACTIN, S1P1/ACTIN, and ICAM1/ACTIN protein ratio, and the
percentage of S1P1-positive-cells of patient T-LBL samples versus T-ALL
samples. Student’s t test was also used to analyze differences in W146-treat-
ments for zebrafish tumor cells in cell culture and the intravasation scores
between Myc;Cre and Myc;Cre;bcl-2 transplanted lymphoma cells, or
between the vehicle and W146-treated Myc;Cre;bcl-2 lymphoma cells.
p values that were equal to or less than 0.05 were considered statistically
significant. p values were not adjusted for multiple comparisons.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found online at doi:10.1016/j.ccr.
2010.09.009
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